- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07848373
Contact Lens-Wearing Dry Eye Subjects Who Are Treated With Acoltremon 0.003%
A Clinical Evaluation of Contact Lens-Wearing Dry Eye Subjects Who Are Treated With Acoltremon 0.003%
Dry Eye Disease is a multifaceted condition which has symptoms such as eye dryness, burning, and stinging sensation in the eyes. As well as clinical diagnosis such as a decreased ability to create tear film. Despite improvements in Contact Lenses (CL) DED still is responsible for a large percentage of CL dropouts due to discomfort. Thus, the purpose of this study is to determine if acoltremon 0.003% can improve the frequency and severity of DED symptoms in CL wearers.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This 1 month 3 visit, single arm open label study aims to determine if acoltremon 0.003% can improve the frequency and severity of Dry Eye Disease (DED) symptoms in CL wearers. DED is a multifactorial condition that can cause stinging, burning sensation or dry eyes. It can also have clinically significant findings such as decreased tear production (aqueous-deficient DED) or increased tear evaporation (evaporative DED). Conditions like this often lead to discomfort, and thus individuals to drop out of wearing contact lenses. With nearly 20% of CL dropouts annually being due to discomfort.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 4
Contatti e Sedi
Contatto studio
- Nome: Chris Lievens, OD, PhD
- Numero di telefono: 901-481-5699
- Email: clievens@sco.edu
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
• Adult subjects who are ≥18 years of age.
- Best corrected CL visual acuity of 0.1 Logarithm of the Minimum Angle of Resolution (logMAR) or better in both eyes (Snellen equivalent 20/25).
- Willing to wear a new pair of CLs to the baseline study visit.
- Daily, soft, frequent replacement CL wearer (daily disposable, bi-weekly, or monthly CLs).
- An Eye Dryness VAS score of ≥40.
- CLDEQ-8 scores (CLDEQ-8 scores ≥12).
- A score of >7 dots on the Lexitas NEI staining scale (grade 1 in a single sector on the 5-sector scale).
- Habitual wearers of soft CLs for a minimum of 5 days per week for 6 hours or more per day during the month prior to enrollment.
- Willing to maintain habitual soft CL wear of a minimum of 5 days per week for 6 or more hours per day for the 1 month duration of the study.
- Habitual CLs have an acceptable fit (good centration, movement, and coverage
Exclusion Criteria:
- Any history of acoltremon 0.003% use.
- Are currently an overnight CL wearer.
- Are currently hard or scleral CL wearers.
- Have known systemic health conditions that are known to alter tear film physiology (e.g., primary and secondary Sjögren's syndrome).
- Have a history of ocular surgery within the past 12 months.
- Have a history of viral eye disease that may confound study results.
- Have a history of severe ocular trauma, active ocular infection or inflammation.
- Have ever used isotretinoin-derivates (e.g., Accutane).
- Are currently taking ocular medications (including topical glaucoma medication) or plan to during the study.
- Have had a physical meibomian gland treatment withing 1 month of enrollment (iLux, Lipiflow, Radio Frequency and IPL with manual expressions, microblepharoexfoliation etc.).
- Have used a prescription DED medication in the last 1 month.
- Unwilling to agree to discontinue artificial tear use the day before enrollment and throughout the study.
- Have a condition or in a situation, which in the examiner's opinion, may put the subject at significant risk, may confound the study results, or may significantly interfere with their participation.
- Are pregnant or breast feeding.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: acoltremon 0.003%
participants will be provided with acoltremon 0.003% and instructed to use it twice a day. |
Acoltremon 0.003% (TRYPTYR; Alcon Laboratories; Fort Worth, TX, USA) was recently approved by the US Food and Drug Administration (FDA) as the first transient receptor potential melastatin (TRPM8) agonist for the treatment of DED. Acoltremon 0.003% is dosed twice a day |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Eye Dryness Score (VAS) at 4 weeks compared to baseline
Lasso di tempo: 1 month
|
participants will be asked to evaluate their eye dryness using a VAS scale with higher numbers indicating greater comfort. |
1 month
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Eye Dryness Score (VAS) at 2 weeks compared to baseline
Lasso di tempo: two weeks
|
participants will be asked to complete an eye dryness visual analog scale with higher numbers indicating greater comfort |
two weeks
|
|
CL End of day comfort VAS
Lasso di tempo: 4 weeks
|
participants will be asked to complete a contact lens comfort visual analog scale with higher numbers indicating greater comfort |
4 weeks
|
|
CL End of day comfort VAS
Lasso di tempo: 2 weeks
|
participants will be asked to complete a contact lens comfort visual analog scale with higher numbers indicating greater comfort |
2 weeks
|
|
Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8)
Lasso di tempo: 1 month
|
participants will be asked to complete the CLDEQ-8 questionnaire with lower scores indicating more comfort |
1 month
|
|
Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8)
Lasso di tempo: 2 weeks
|
participants will be asked to complete the CLDEQ-8 questionnaire with lower scores indicating more comfort |
2 weeks
|
Collaboratori e investigatori
Sponsor
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- IRB000673-Acoltremon dry eye
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
An abstract describing the primary outcome will be submitted for ARVO 2027, and a manuscript on the same topic will be submitted to Contact Lens & Anterior Eye or similar publication. An abstract related to the Likert survey results will be submitted to Optometry's Meeting 2027
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .